Ocular Surface Metabolo-lipidomics in Lateral Amyotrophic Sclerosis

Tear Fluid and Ocular Surface Metabolomics and Lipidomics in Lateral Amyotrophic Sclerosis: a Prospective Comparative Study

Amyotrophic Lateral Sclerosis (ALS) is the most common neurodegenerative disease affecting the motor neuron. Currently, there is no diagnostic test and no examination that can predict the evolution of this pathology. The search for diagnostic and prognostic biomarkers is therefore essential for a better understanding of the pathophysiology of ALS, which remains poorly understood, and also for better clinical management. The ocular surface, made up of liquid elements, tears, and cells, is an accessible anatomical-physiological entity that has demonstrated its usefulness in the identification of biomarkers in neurodegenerative diseases such as Parkinson's or Alzheimer's. To date, no study has explored the ocular surface as a biomarker in ALS

Case group selection criteria :

Inclusion Criteria:

• Patient with clinically defined or probable primary ALS according to Airlie House criteria(1)
• Familial or sporadic form
• ≥18 years of age
• Patient affiliated with a social security plan
• Informed consent signed by the patient

Exclusion Criteria:

• Motor neuron disease mimicking ALS
• Pregnant or breastfeeding woman
• Treatment that may have a neuroprotective effect
• Any eye drops or treatments that may interfere with tear production
• Lens wearer
• Eye surgery ≤3 months
• Any ocular pathology other than ametropia, oculomotor disorder, amblyopia
• Any general pathology other than ALS with ocular repercussions
• Protective measure of guardianship or curators

Control group selection criteria:

Inclusion Criteria:

• No diagnosed neurological pathology
• ≥18 years of age
• Patient affiliated with a social security plan
• Informed consent signed by the participant

Exclusion Criteria:

• Pregnant or breastfeeding woman
• Treatment likely to have a neuroprotective effect
• Any eye drops or treatments that may interfere with tear production
• Lens wearer
• Eye surgery ≤3 months
• Any ocular pathology except ametropia, oculomotor disorder, amblyopia
• Any general pathology with ocular repercussions
• Protective measure of guardianship or curator